HOPE study
Also written as: HOPE — Heart Outcomes Prevention Evaluation
Influential trial proving cardiovascular benefits of ramipril in high-risk patients without heart failure.
Full Definition
The Heart Outcomes Prevention Evaluation (HOPE) study was a landmark randomized controlled trial that demonstrated the cardiovascular protective effects of the ACE inhibitor ramipril in high-risk patients without left ventricular dysfunction or heart failure. Published in 2000, HOPE showed a 22% reduction in cardiovascular death, myocardial infarction, and stroke. The trial was groundbreaking because it extended ACE inhibitor benefits beyond heart failure patients and established ramipril as a cornerstone of cardiovascular prevention therapy.
Usage
Usage note: Capitalize all letters; distinguish from HOPE-3 and other HOPE substudies
In Context
- "The HOPE study fundamentally changed cardiovascular prevention by demonstrating ACE inhibitor benefits in high-risk patients." — Historical review article
- "Ramipril dosing in clinical practice often follows the HOPE study protocol of 10 mg daily." — Prescribing guidance document